384 related articles for article (PubMed ID: 31999199)
1. Healthcare resource utilization and direct medical costs associated with index and recurrent
Feuerstadt P; Stong L; Dahdal DN; Sacks N; Lang K; Nelson WW
J Med Econ; 2020 Jun; 23(6):603-609. PubMed ID: 31999199
[No Abstract] [Full Text] [Related]
2. Health care resource utilization and costs of recurrent
Nelson WW; Scott TA; Boules M; Teigland C; Parente A; Unni S; Feuerstadt P
J Manag Care Spec Pharm; 2021 Jul; 27(7):828-838. PubMed ID: 33703939
[No Abstract] [Full Text] [Related]
3. Attributable Healthcare Resource Utilization and Costs for Patients With Primary and Recurrent Clostridium difficile Infection in the United States.
Zhang D; Prabhu VS; Marcella SW
Clin Infect Dis; 2018 Apr; 66(9):1326-1332. PubMed ID: 29360950
[TBL] [Abstract][Full Text] [Related]
4. Healthcare burden of recurrent Clostridioides difficile infection in Japan: A retrospective database study.
Kunishima H; Ito K; Laurent T; Abe M
J Infect Chemother; 2018 Nov; 24(11):892-901. PubMed ID: 30190105
[TBL] [Abstract][Full Text] [Related]
5. Economic Impact of Recurrent Clostridioides difficile Infection in the USA: A Systematic Literature Review and Cost Synthesis.
Reveles KR; Yang M; Garcia-Horton V; Edwards ML; Guo A; Lodise T; Bochan M; Tillotson G; Dubberke ER
Adv Ther; 2023 Jul; 40(7):3104-3134. PubMed ID: 37210680
[TBL] [Abstract][Full Text] [Related]
6. Mortality, Health Care Use, and Costs of Clostridioides difficile Infections in Older Adults.
Feuerstadt P; Nelson WW; Drozd EM; Dreyfus J; Dahdal DN; Wong AC; Mohammadi I; Teigland C; Amin A
J Am Med Dir Assoc; 2022 Oct; 23(10):1721-1728.e19. PubMed ID: 35288083
[TBL] [Abstract][Full Text] [Related]
7. Mortality, healthcare resource utilization, and cost among Medicare beneficiaries with
Amin A; Nelson WW; Dreyfus J; Wong AC; Mohammadi I; Teigland C; Dahdal DN; Feuerstadt P
Ther Adv Infect Dis; 2022; 9():20499361221095679. PubMed ID: 35510091
[TBL] [Abstract][Full Text] [Related]
8. Impact of recurrent Clostridium difficile infection: hospitalization and patient quality of life.
Wilcox MH; Ahir H; Coia JE; Dodgson A; Hopkins S; Llewelyn MJ; Settle C; Mclain-Smith S; Marcella SW
J Antimicrob Chemother; 2017 Sep; 72(9):2647-2656. PubMed ID: 28633368
[TBL] [Abstract][Full Text] [Related]
9. Predictors and burden of hospital readmission with recurrent Clostridioides difficile infection: a French nation-wide inception cohort study.
Dinh A; Le Monnier A; Emery C; Alami S; Torreton É; Duburcq A; Barbier F
Eur J Clin Microbiol Infect Dis; 2019 Jul; 38(7):1297-1305. PubMed ID: 30941532
[TBL] [Abstract][Full Text] [Related]
10. Clinical burden of recurrent
Feuerstadt P; Nelson WW; Teigland C; Dahdal DN
Antimicrob Steward Healthc Epidemiol; 2022; 2(1):e60. PubMed ID: 36483433
[TBL] [Abstract][Full Text] [Related]
11. Clinical complications in patients with primary and recurrent
Feuerstadt P; Boules M; Stong L; Dahdal DN; Sacks NC; Lang K; Nelson WW
SAGE Open Med; 2021; 9():2050312120986733. PubMed ID: 33505698
[TBL] [Abstract][Full Text] [Related]
12. Characterization and risk factors for recurrence of Clostridioides (Clostridium) difficile infection in Japan: A nationwide real-world analysis using a large hospital-based administrative dataset.
Kimura T; Snijder R; Sugitani T
J Infect Chemother; 2019 Aug; 25(8):615-620. PubMed ID: 30987950
[TBL] [Abstract][Full Text] [Related]
13. Epidemiological and clinical burden of Clostridioides difficile infections and recurrences between 2015 - 2019: the RECUR Germany study.
Tricotel A; Antunes A; Wilk A; Dombrowski S; Rinta-Kokko H; Andersson FL; Ghosh S
BMC Infect Dis; 2024 Mar; 24(1):357. PubMed ID: 38539166
[TBL] [Abstract][Full Text] [Related]
14. Economic burden of recurrent Clostridioides difficile infection in adults admitted to Spanish hospitals. A multicentre retrospective observational study.
Bouza E; Cobo J; Rodríguez-Hernández MJ; Salavert M; Horcajada JP; Iribarren JA; Obi E; Lozano V; Maratia S; Cuesta M; Uría E; Limón E
Rev Esp Quimioter; 2021 Apr; 34(2):126-135. PubMed ID: 33618513
[TBL] [Abstract][Full Text] [Related]
15. Cost-Effectiveness Analysis of REBYOTA™ (Fecal Microbiota, Live-jslm [FMBL]) Versus Standard of Care for the Prevention of Recurrent Clostridioides difficile Infection in the USA.
Lodise T; Guo A; Yang M; Cook EE; Song W; Yang D; Wang Q; Zhao A; Bochan M
Adv Ther; 2023 Jun; 40(6):2784-2800. PubMed ID: 37093359
[TBL] [Abstract][Full Text] [Related]
16. Healthcare resource use and attributable cost of Clostridium difficile infection: a micro-costing analysis comparing first and recurrent episodes.
Tresman R; Goldenberg SD
J Antimicrob Chemother; 2018 Oct; 73(10):2851-2855. PubMed ID: 29982502
[TBL] [Abstract][Full Text] [Related]
17. Clostridioides difficile infections, recurrences, and clinical outcomes in real-world settings from 2015 to 2019: The RECUR England study.
Ghosh S; Antunes A; Rinta-Kokko H; Chaparova E; Lay-Flurrie S; Tricotel A; Andersson FL
Int J Infect Dis; 2024 Mar; 140():31-38. PubMed ID: 38185320
[TBL] [Abstract][Full Text] [Related]
18. A Comprehensive Study of Costs Associated With Recurrent Clostridium difficile Infection.
Rodrigues R; Barber GE; Ananthakrishnan AN
Infect Control Hosp Epidemiol; 2017 Feb; 38(2):196-202. PubMed ID: 27817758
[TBL] [Abstract][Full Text] [Related]
19. Excess length of hospital stay, mortality and cost attributable to
Kimura T; Stanhope S; Sugitani T
Epidemiol Infect; 2020 Mar; 148():e65. PubMed ID: 32115019
[TBL] [Abstract][Full Text] [Related]
20. Budget Impact Analysis of REBYOTA™ (Fecal Microbiota, Live-jslm [FMBL]) for Preventing Recurrent Clostridioides difficile Infection in the US.
Lodise T; Guo A; Yang M; Cook EE; Song W; Yang D; Wang Q; Zhao A; Bochan M
Adv Ther; 2023 Jun; 40(6):2801-2819. PubMed ID: 37093360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
